DNTH Dianthus Corp: רווח נקי למניה ב-12 החודשים האחרונים

Dianthus Therapeutics (DNTH) is optimizing protein synthesis costs through contract diversification to ensure high margins. The current YoY TTM EPS growth rate reflects the price action, where the parameter value equals -14.10. Revenues are based on insurance fund procurement for the treatment of rare pathologies. Independence from macroeconomic factors makes the asset a defensive tool during periods of global recession.
Dianthus Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (DNTH)

This indicator measures the rolling annual growth rate of earnings per share, allowing for an assessment of the business's actual capitalization efficiency without market noise. Analyzing the EPS TTM annual trend chart is critically important for Dianthus Therapeutics (DNTH), as it reflects the company's financial stability during the development of the DNTH-103 drug and preparations for new phases of clinical trials.